COMPARISON
Ganirelix vs Leuprolide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Ganirelix is authorised or registered in 10 and Leuprolide in 8 of the 10 registers read. Ganirelix: highest phase Phase 4 (after approval). Leuprolide: highest phase Phase 3 (2 phase 3 trials, 0 with posted results). 6 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Ganirelix | Leuprolide | |
|---|---|---|
| Registered trials differs | 108 clinicaltrials.gov · 2026-10-03 | 520 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Ganirelix Acetate openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Vabrinty openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Authorised ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU authorised on differs | 2000-05-16 ema · 2026-10-03 | Not checked no record of "authorisedOn" for leuprolide |
| ATC code differs | H01CC01 ema · 2026-10-03 | Not checked no record of "atcCode" for leuprolide |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Ganirelix | placebo | Leuprolide | placebo |
|---|---|---|---|---|
| Hot flush | - | - | 68.8% | 57.3% |
| Fatigue | - | - | 42.8% | 32.8% |
| Arthralgia | - | - | 27.5% | 20.9% |
| Fall | - | - | 20.4% | 14.1% |
| Back pain | - | - | 17.0% | 15.3% |
| Hypertension | - | - | 16.4% | 15.1% |
| Diarrhoea | - | - | 13.9% | 8.5% |
| Asthenia | - | - | 11.0% | 5.9% |
| Pain in extremity | - | - | 11.0% | 10.2% |
| Dizziness | - | - | 11.0% | 10.5% |
Trial register Ganirelix: 0 placebo-controlled trials; Leuprolide: 2. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Ganirelix side effects · Leuprolide side effects
LEGAL STATUS
Approval in each country read
| Country | Ganirelix | Leuprolide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Status unknown | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Authorised | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Ruhsatli | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
6 registered trials include both
| NCT00633555 | A Comparison of the Microdose Leuprolide Protocol vs. Luteal Phase Ganirelix Protocol in Women Who Are or Who Are Predicted to be Low Responders COMPLETED · updated 2018-05-25 |
|---|---|
| NCT02069808 | Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation COMPLETED · updated 2018-03-23 |
| NCT00734279 | Follicle-Stimulating Hormone (FSH) and the Onset of Puberty COMPLETED · updated 2017-12-26 |
| NCT01669291 | Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation COMPLETED · updated 2014-06-04 |
| NCT00826839 | Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients WITHDRAWN · updated 2013-06-25 |
| NCT01424618 | A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs UNKNOWN · updated 2011-08-29 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.